BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 18812595)

  • 1. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia.
    Kratzer A; Buchebner M; Pfeifer T; Becker TM; Uray G; Miyazaki M; Miyazaki-Anzai S; Ebner B; Chandak PG; Kadam RS; Calayir E; Rathke N; Ahammer H; Radovic B; Trauner M; Hoefler G; Kompella UB; Fauler G; Levi M; Levak-Frank S; Kostner GM; Kratky D
    J Lipid Res; 2009 Feb; 50(2):312-26. PubMed ID: 18812595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor.
    Quinet EM; Savio DA; Halpern AR; Chen L; Miller CP; Nambi P
    J Lipid Res; 2004 Oct; 45(10):1929-42. PubMed ID: 15292374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.
    Quinet EM; Savio DA; Halpern AR; Chen L; Schuster GU; Gustafsson JA; Basso MD; Nambi P
    Mol Pharmacol; 2006 Oct; 70(4):1340-9. PubMed ID: 16825483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/- mice.
    Dai XY; Ou X; Hao XR; Cao DL; Tang YL; Hu YW; Li XX; Tang CK
    J Cardiovasc Pharmacol; 2008 May; 51(5):467-75. PubMed ID: 18437096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.
    Peng D; Hiipakka RA; Dai Q; Guo J; Reardon CA; Getz GS; Liao S
    J Pharmacol Exp Ther; 2008 Nov; 327(2):332-42. PubMed ID: 18723776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiatherosclerotic effect of farnesoid X receptor.
    Mencarelli A; Renga B; Distrutti E; Fiorucci S
    Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H272-81. PubMed ID: 19028791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype.
    Lund EG; Peterson LB; Adams AD; Lam MH; Burton CA; Chin J; Guo Q; Huang S; Latham M; Lopez JC; Menke JG; Milot DP; Mitnaul LJ; Rex-Rabe SE; Rosa RL; Tian JY; Wright SD; Sparrow CP
    Biochem Pharmacol; 2006 Feb; 71(4):453-63. PubMed ID: 16325781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol.
    Beyea MM; Heslop CL; Sawyez CG; Edwards JY; Markle JG; Hegele RA; Huff MW
    J Biol Chem; 2007 Feb; 282(8):5207-16. PubMed ID: 17186944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
    Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on LXR- and FXR-mediated effects on cholesterol homeostasis in normal and cholic acid-depleted mice.
    Wang J; Einarsson C; Murphy C; Parini P; Björkhem I; Gåfvels M; Eggertsen G
    J Lipid Res; 2006 Feb; 47(2):421-30. PubMed ID: 16264196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice.
    Teupser D; Kretzschmar D; Tennert C; Burkhardt R; Wilfert W; Fengler D; Naumann R; Sippel AE; Thiery J
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2009-15. PubMed ID: 18787185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR.
    Cha JY; Repa JJ
    J Biol Chem; 2007 Jan; 282(1):743-51. PubMed ID: 17107947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of ASC-2 as an antiatherogenic transcriptional coactivator of liver X receptors in macrophages.
    Kim GH; Park K; Yeom SY; Lee KJ; Kim G; Ko J; Rhee DK; Kim YH; Lee HK; Kim HW; Oh GT; Lee KU; Lee JW; Kim SW
    Mol Endocrinol; 2009 Jul; 23(7):966-74. PubMed ID: 19342446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-specific autoregulation of the LXRalpha gene facilitates induction of apoE in mouse adipose tissue.
    Ulven SM; Dalen KT; Gustafsson JA; Nebb HI
    J Lipid Res; 2004 Nov; 45(11):2052-62. PubMed ID: 15292368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-steroidal LXR agonists; an emerging therapeutic strategy for the treatment of atherosclerosis.
    Bennett DJ; Cooke AJ; Edwards AS
    Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):21-46. PubMed ID: 18221072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR.
    Khovidhunkit W; Moser AH; Shigenaga JK; Grunfeld C; Feingold KR
    J Lipid Res; 2003 Sep; 44(9):1728-36. PubMed ID: 12777468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms.
    Verschuren L; de Vries-van der Weij J; Zadelaar S; Kleemann R; Kooistra T
    J Lipid Res; 2009 Feb; 50(2):301-11. PubMed ID: 18757914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions.
    Marleau S; Harb D; Bujold K; Avallone R; Iken K; Wang Y; Demers A; Sirois MG; Febbraio M; Silverstein RL; Tremblay A; Ong H
    FASEB J; 2005 Nov; 19(13):1869-71. PubMed ID: 16123174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol.
    Pfeifer T; Buchebner M; Chandak PG; Patankar J; Kratzer A; Obrowsky S; Rechberger GN; Kadam RS; Kompella UB; Kostner GM; Kratky D; Levak-Frank S
    Curr Pharm Biotechnol; 2011 Feb; 12(2):285-92. PubMed ID: 21190543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cholesterol, cholic acid and cholestyramine administration on the intestinal mRNA expressions related to cholesterol and bile acid metabolism in the rat.
    Kamisako T; Ogawa H; Yamamoto K
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1832-7. PubMed ID: 17498222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.